OssDsign USA Inc.

OssDsign is a Swedish medtech company specializing in next-generation orthobiological products for bone regeneration and spinal fusion surgery. Founded in 2011 through collaboration between Uppsala University and Karolinska University, the company became publicly listed on Nasdaq First North Growth Market in 2019. OssDsign focuses exclusively on orthobiologics following its transition away from cranial implants in January 2024. The company's flagship product, OssDsign Catalyst, is a nanosynthetic bone graft putty designed for interbody spinal fusion applications. Catalyst engages dual bone formation pathways to promote rapid and reliable bone formation throughout the fusion mass and was the first synthetic bone graft cleared to market for interbody use based on bone graft data alone, enabling on-label use in any interbody cage cleared for synthetic bone grafts. The product has demonstrated clinical efficacy through peer-reviewed studies and real-world outcome registries since its U.S. market launch in late 2021. With approximately 50 employees, OssDsign operates at the intersection of material science and orthopedic surgery, addressing unmet needs in spinal fusion procedures.